Your browser is no longer supported. Please, upgrade your browser.
CERC [NASD]
Cerecor Inc.
Index- P/E- EPS (ttm)-1.01 Insider Own0.20% Shs Outstand74.99M Perf Week-19.12%
Market Cap213.14M Forward P/E- EPS next Y-0.31 Insider Trans- Shs Float40.31M Perf Month-15.38%
Income-64.40M PEG- EPS next Q-0.19 Inst Own66.30% Short Float5.71% Perf Quarter-44.44%
Sales6.70M P/S31.81 EPS this Y-154.40% Inst Trans25.78% Short Ratio1.27 Perf Half Y0.92%
Book/sh0.33 P/B6.67 EPS next Y51.60% ROA-117.40% Target Price- Perf Year-1.79%
Cash/sh0.20 P/C11.28 EPS next 5Y- ROE-182.40% 52W Range1.98 - 4.50 Perf YTD-16.67%
Dividend- P/FCF- EPS past 5Y4.50% ROI-284.80% 52W High-51.11% Beta1.58
Dividend %- Quick Ratio1.70 Sales past 5Y- Gross Margin95.50% 52W Low11.11% ATR0.28
Employees32 Current Ratio1.70 Sales Q/Q-77.90% Oper. Margin- RSI (14)32.68 Volatility15.70% 10.25%
OptionableYes Debt/Eq0.00 EPS Q/Q43.30% Profit Margin- Rel Volume0.65 Prev Close2.25
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.81M Price2.20
Recom1.30 SMA20-17.14% SMA50-23.93% SMA200-20.33% Volume1,178,413 Change-2.22%
Apr-20-21Initiated Jefferies Buy $4
Mar-13-20Downgrade Maxim Group Buy → Hold
Jan-10-20Initiated Oppenheimer Outperform
Apr-09-19Initiated Maxim Group Buy $10
Apr-01-19Initiated H.C. Wainwright Buy $11
Dec-20-18Initiated Ladenburg Thalmann Buy
Dec-12-16Downgrade Rodman & Renshaw Buy → Neutral $4 → $1
Apr-13-16Initiated Rodman & Renshaw Buy $15
Dec-09-15Initiated Laidlaw Buy $10
May-13-21 07:00AM  
May-11-21 09:15AM  
07:33AM  
07:00AM  
May-05-21 07:00AM  
Mar-29-21 08:33AM  
07:00AM  
Mar-08-21 04:01PM  
Mar-04-21 07:00AM  
Mar-02-21 08:47AM  
08:01AM  
07:00AM  
Mar-01-21 07:00AM  
Feb-25-21 12:17AM  
Feb-08-21 08:16AM  
Feb-02-21 07:00AM  
Jan-20-21 07:00AM  
Jan-12-21 04:01PM  
Jan-07-21 10:03PM  
04:01PM  
Jan-05-21 08:38AM  
07:00AM  
Dec-22-20 01:00PM  
Dec-16-20 07:00AM  
Dec-10-20 11:32PM  
Dec-08-20 07:00AM  
Dec-01-20 07:00AM  
Nov-27-20 12:17AM  
Nov-17-20 07:00AM  
Nov-16-20 07:10AM  
Nov-09-20 04:01PM  
Oct-26-20 11:55PM  
Oct-12-20 07:00AM  
Sep-10-20 07:00AM  
Aug-26-20 07:00AM  
Aug-13-20 09:00AM  
07:00AM  
Aug-12-20 07:56AM  
07:47AM  
Aug-06-20 07:00AM  
Aug-05-20 07:00AM  
Aug-04-20 07:00AM  
Aug-03-20 07:00AM  
Jul-21-20 07:00AM  
Jun-13-20 09:01AM  
Jun-12-20 11:42AM  
Jun-11-20 01:30PM  
Jun-10-20 04:18PM  
Jun-09-20 09:05AM  
Jun-08-20 04:01PM  
09:49AM  
May-29-20 07:00AM  
May-28-20 07:00AM  
May-26-20 07:00AM  
May-13-20 06:00AM  
May-07-20 06:30AM  
May-04-20 09:15AM  
Apr-24-20 01:45PM  
Mar-27-20 09:39PM  
Mar-26-20 06:30AM  
Mar-19-20 08:50AM  
Mar-13-20 07:18AM  
06:59AM  
Mar-11-20 06:30AM  
Mar-06-20 09:00AM  
Feb-04-20 01:31PM  
Feb-03-20 04:15PM  
Dec-23-19 10:26AM  
Dec-13-19 09:50AM  
Dec-10-19 03:20PM  
Dec-05-19 08:45AM  
Nov-14-19 06:30AM  
Nov-11-19 06:30AM  
Nov-04-19 06:30AM  
Oct-23-19 11:27AM  
Oct-14-19 06:30AM  
Aug-21-19 07:42AM  
06:30AM  
Aug-08-19 04:05PM  
Jul-29-19 06:30AM  
Jul-25-19 03:22PM  
Jul-23-19 10:00AM  
Jul-15-19 06:30AM  
Jul-02-19 12:03PM  
Jul-01-19 06:30AM  
Jun-28-19 02:19PM  
06:30AM  
Jun-12-19 04:05PM  
Jun-11-19 01:00PM  
May-13-19 02:00PM  
May-09-19 04:05PM  
Apr-29-19 10:38AM  
06:30AM  
Apr-17-19 10:15AM  
Apr-15-19 06:30AM  
Apr-11-19 06:30AM  
Mar-26-19 10:30AM  
Mar-18-19 04:05PM  
Mar-06-19 06:05AM  
Mar-05-19 05:30PM  
Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare and orphan diseases. The company develops monosaccharide therapies for the treatment of congenital disorders of glycosylation, such as CERC-801, CERC-802, and CERC-803. It is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of adult onset stills disease and multiple myeloma, as well as for the treatment of systemic juvenile idiopathic arthritis; CERC-006, an oral mTORC1/2 inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody that is in phase 2 clinical trial for the treatment of COVID-19 acute respiratory distress syndrome, as well as for the treatment of pediatric-onset Crohn's diseases. In addition, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. Cerecor Inc. has a collaboration agreement with The Frontiers in Congenital Disorders of Glycosylation Consortium on pivotal trial of CERC-801 for the treatment of Phosphoglucomutase-1 deficiency related congenital disorders of glycosylation. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ARMISTICE CAPITAL, LLCDirectorJan 08Buy2.602,500,0006,500,00032,634,285Jan 12 05:22 PM
Harrell James Archie JrChief Commercial OfficerDec 10Buy2.2817139028,180Dec 14 04:17 PM
Sullivan Christopher RyanInterim CFODec 10Buy2.285,09511,6068,049Dec 14 04:12 PM
NEIL GARRY ARTHURChief Scientific OfficerDec 10Buy2.283,5998,19977,680Dec 14 04:06 PM
ARMISTICE CAPITAL, LLCDirectorDec 03Buy2.4420,00048,80030,134,285Dec 07 06:26 PM
ARMISTICE CAPITAL, LLC10% OwnerNov 25Buy2.3915,00035,85030,114,285Nov 25 06:05 PM
ARMISTICE CAPITAL, LLC10% OwnerNov 24Buy2.4047,733114,55930,099,285Nov 25 06:05 PM
ARMISTICE CAPITAL, LLC10% OwnerNov 23Buy2.3237,26786,45930,051,552Nov 25 06:05 PM
ARMISTICE CAPITAL, LLCDirectorSep 04Buy2.20100,000220,00030,014,285Sep 09 06:57 PM
ARMISTICE CAPITAL, LLCDirectorJun 11Buy2.4428,00068,3201,128,000Jun 11 05:54 PM
Harrell James Archie JrChief Commercial OfficerJun 10Buy2.286,39114,55928,009Jun 11 09:42 PM
Sullivan Christopher RyanInterim CFOJun 10Buy2.282,9546,7292,954Jun 11 09:08 PM
NEIL GARRY ARTHURChief Scientific OfficerJun 10Buy2.281,7994,09874,081Jun 11 09:02 PM
COLA MICHAEL FChief Executive OfficerJun 09Buy2.50100,000250,000175,746Jun 11 08:28 PM
Harrell James Archie JrChief Commercial OfficerJun 09Buy2.5010,00025,00021,618Jun 11 09:42 PM
ARMISTICE CAPITAL, LLCDirectorJun 09Buy2.52267,806674,8711,100,000Jun 11 05:54 PM
ARMISTICE CAPITAL, LLCDirectorJun 09Buy2.501,753,6804,384,20029,914,285Jun 11 05:54 PM